A Phase 3 interventional study of Olaparib and Olaparib in Germline BRCA1/2 Mutations and and Metastatic Adenocarcinoma of the Pancreas, sponsored by AstraZeneca. Completed at 103 sites in 12 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2023-09-13.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing olaparib in Pancreatic Neoplasms — 4 open to participants now, 7 under way, none of them phase 3. olaparib · Pancreatic Neoplasms.
Among the 14 studies testing olaparib in Pancreatic Neoplasms, this one is the 2nd largest by enrollment, is the only one that started in 2014, is the only one in phase 3, and was the 3rd registered.
3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.
Browse Pancreatic Neoplasms studies →4 of the 14 studies testing olaparib in Pancreatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
Azienda Ospedaliero-Universitaria di Modena · Sites in Italy
Ages 18+
National Cancer Institute (NCI) · Sites in United States, Israel, Puerto Rico
Ages 18+
OHSU Knight Cancer Institute · Sites in United States
Ages 18+
Herlev Hospital · Sites in Denmark
Ages 18+
By country, each count listing its studies:
olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, olaparib is the treatment under test here. Read study by study →
14 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 154 is above the median of 47 across 2,932 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 30 across the 14 interventional studies. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 14 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
19 studies in Pancreatic Neoplasms by AstraZeneca: 3 open now, 5 under way, none of them phase 3. Of 14 finished, 4 (29%) have results posted.
Among the 19 studies in Pancreatic Neoplasms by AstraZeneca, this one is the 5th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2014, is the only one in phase 3, and was the 6th registered.
AstraZeneca’s Pancreatic Neoplasms studies by the year they started, since 2002.
3 of the studies testing olaparib in Pancreatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05093231Cambridge University Hospitals NHS Foundation TrustPembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer | 2026-11-30 |
| NCT04005690OHSU Knight Cancer InstituteTargeted Pathway Inhibition in Patients With Pancreatic Cancer | 2027-06-01 |
| NCT04858334National Cancer Institute (NCI)APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | 2027-10-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies testing olaparib in Pancreatic Neoplasms, from their registry updates:
Among AstraZeneca’s 19 in Pancreatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy
Approximately 145 patients will be randomised using an Interactive Voice Response System /Interactive Web Response System (IVR/IWR system) in a 3:2 ratio (Olaparib:placebo) to the treatments as specified below:
Patients will be randomised within 6 weeks after their last dose of chemotherapy (last dose is the day of the last infusion) and treatment started as soon as possible but no less than 4 and no more than 8 weeks of the last chemotherapy dose. At the time of starting protocol treatment, all previous chemotherapy treatment should be discontinued.
Following randomisation, patients will attend clinic visits weekly for the first 4 weeks of treatment (Days 8, 15, 22 and 29). Patients will then attend clinic visits every 4 weeks whilst on study treatment. Patients should continue to receive study treatment until objective radiological disease progression as per RECIST as assessed by the investigator and as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria.
Once a patient has progressed the patient will be followed for second progression (PFS2) every 8 weeks and then survival until the final analysis.
Key Inclusion Criteria
Major Exclusion Criteria:
Cytotoxic chemotherapy or non-hormonal targeted therapy within 28 days of Cycle
1 Day 1 is not permitted.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Olaparib tablets po. 300 mg twice daily
Drug: Olaparib
Placebo tablets twice daily
Drug: Placebo
Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) Using Modified Response Evaluation Criteria in Solid Tumours. This Study Used Modified RECIST Version (v) 1.1 (RECIST v1.1)
To determine the efficacy of olaparib maintenance monotherapy compared to placebo by PFS. The PFS was defined as the time from randomisation until the date of objective radiological disease progression according to modified RECIST v1.1 or death (by any cause in the absence of disease progression) regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to disease progression.
Time frame: Up to 4 years
Overall Survival (OS)
To determine the efficacy by assessment of OS of olaparib maintenance monotherapy compared to placebo. The OS was defined as the time from the date of randomization until death due to any cause.
Time frame: Upto 4 years
Time From Randomisation to Second Progression (PFS2)
To determine efficacy by assessment of PFS2 of olaparib maintenance monotherapy compared to placebo. The PFS2 was defined as the time from the date of randomisation to the earliest of the progression event subsequent to that used for the primary variable PFS or death.
Time frame: Up to 4 years
Time From Randomisation to Second Subsequent Therapy or Death (TSST)
To determine the efficacy by assessment of TSST of olaparib maintenance monotherapy compared to placebo. The TSST was defined as time to second subsequent therapy or death.
Time frame: Up to 4 years
Time From Randomisation to First Subsequent Therapy or Death (TFST)
To determine the efficacy by assessment of TFST of olaparib maintenance monotherapy compared to placebo. The TFST was defined as time to first subsequent therapy or death.
Time frame: Up to 4 years
Time From Randomisation to Study Treatment Discontinuation or Death (TDT)
To determine the efficacy by assessment of TDT compared to placebo. compared to placebo. The TDT was defined as time to study treatment discontinuation or death.
Time frame: Up to 4 years
Number of Participants With Objective Response Rate (ORR) by BICR Using Modified RECIST 1.1
To determine efficacy by assessment of objective response rate according to modified RECIST 1.1 of olaparib maintenance monotherapy compared to placebo. The ORR is defined as the number of with a BoR of CR and PR according to the BICR data divided by the number of patients in the treatment group with measurable disease at baseline.
Time frame: Up to 4 years
Disease Control Rate (DCR) by BICR Using Modified RECIST 1.1
Efficacy by assessment of disease control rate according to modified RECIST 1.1 of olaparib maintenance monotherapy compared to placebo.
Time frame: At 16 weeks
Adjusted Mean Change From Baseline up to 6 Months in Global Quality of Life (QoL) Score From the EORTC-QLQ-C30 Questionnaire
To assess the effect of olaparib on health-related quality of life (QoL) as measured by the EORTC-QLQ-C30 global QoL scale. The EORTC-QLQ-C30 is defined as EORTC QLQ-C30: a questionnaire (30 questions) used to evaluate disease symptoms, functional impacts (eg, physical functioning), and HRQoL and to characterize clinical benefit from the patient perspective. The HRQoL score ranges from 0 to 100. A higher score indicates better QoL. A score change of 10 points was pre-defined as clinically meaningful. bd twice daily.
Time frame: From baseline up to 6 months
Number of Participants With Adverse Events (AEs)
To assess the safety and tolerability of olaparib maintenance monotherapy. SAE: serious adverse events CTCAE: Common Terminology Criteria for Adverse Events
Time frame: Up to 4 years
This study randomised patients at a total of 59 study centres in 12 countries: United States of America (13), Germany (8), France (7), Israel (7), Spain (7), United Kingdom (6), Italy (4), Belgium (2), Republic of Korea (2), Australia (1), Canada (1) and Netherlands (1).
| Milestone | Olaparib 300 mg Twice Daily (bd) | Placebo |
|---|---|---|
| Started | 92 | 62 |
| Completed | 19 | 7 |
| Not completed | 73 | 55 |
| Withdrew: Patient decision | 5 | 2 |
| Withdrew: Eligibility criteria not fulfilled | 0 | 1 |
| Withdrew: Death | 67 | 44 |
| Withdrew: Lost to follow-up | 1 | 5 |
| Withdrew: Other | 0 | 3 |
To determine the efficacy of olaparib maintenance monotherapy compared to placebo by PFS. The PFS was defined as the time from randomisation until the date of objective radiological disease progression according to modified RECIST v1.1 or death (by any cause in the absence of disease progression) regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to disease progression.
| Months | Olaparib 300 mg Twice Daily (bd) | Placebo |
|---|---|---|
| Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) Using Modified Response Evaluation Criteria in Solid Tumours. This Study Used Modified RECIST Version (v) 1.1 (RECIST v1.1) | 7.4 (4.14 to 11.01) | 3.8 (3.52 to 4.86) |
To determine the efficacy by assessment of OS of olaparib maintenance monotherapy compared to placebo. The OS was defined as the time from the date of randomization until death due to any cause.
| Months | Olaparib 300 mg Twice Daily (bd) | Placebo |
|---|---|---|
| Overall Survival (OS) | 19.0 (15.28 to 26.32) | 19.2 (14.32 to 26.12) |
To determine efficacy by assessment of PFS2 of olaparib maintenance monotherapy compared to placebo. The PFS2 was defined as the time from the date of randomisation to the earliest of the progression event subsequent to that used for the primary variable PFS or death.
| Months | Olaparib 300 mg Twice Daily (bd) | Placebo |
|---|---|---|
| Time From Randomisation to Second Progression (PFS2) | 16.9 (8.21 to 23.85) | 9.3 (8.15 to 13.54) |
To determine the efficacy by assessment of TSST of olaparib maintenance monotherapy compared to placebo. The TSST was defined as time to second subsequent therapy or death.
| Months | Olaparib 300 mg Twice Daily (bd) | Placebo |
|---|---|---|
| Time From Randomisation to Second Subsequent Therapy or Death (TSST) | 14.9 (9.13 to 19.78) | 9.6 (8.34 to 12.98) |
To determine the efficacy by assessment of TFST of olaparib maintenance monotherapy compared to placebo. The TFST was defined as time to first subsequent therapy or death.
| Months | Olaparib 300 mg Twice Daily (bd) | Placebo |
|---|---|---|
| Time From Randomisation to First Subsequent Therapy or Death (TFST) | 9.0 (6.21 to 12.85) | 5.4 (3.94 to 6.21) |
To determine the efficacy by assessment of TDT compared to placebo. compared to placebo. The TDT was defined as time to study treatment discontinuation or death.
| Months | Olaparib 300 mg Twice Daily (bd) | Placebo |
|---|---|---|
| Time From Randomisation to Study Treatment Discontinuation or Death (TDT) | 7.5 (5.52 to 10.97) | 3.8 (3.61 to 4.80) |
To determine efficacy by assessment of objective response rate according to modified RECIST 1.1 of olaparib maintenance monotherapy compared to placebo. The ORR is defined as the number of with a BoR of CR and PR according to the BICR data divided by the number of patients in the treatment group with measurable disease at baseline.
| Participants | Olaparib 300 mg Twice Daily (bd) | Placebo |
|---|---|---|
| Number of Participants With Objective Response Rate (ORR) by BICR Using Modified RECIST 1.1 | 22 | 11 |
Efficacy by assessment of disease control rate according to modified RECIST 1.1 of olaparib maintenance monotherapy compared to placebo.
| Participants | Olaparib 300 mg Twice Daily (bd) | Placebo |
|---|---|---|
| Yes | 51 | 24 |
| No | 34 | 34 |
| Not evaluable/missing | 7 | 4 |
To assess the effect of olaparib on health-related quality of life (QoL) as measured by the EORTC-QLQ-C30 global QoL scale. The EORTC-QLQ-C30 is defined as EORTC QLQ-C30: a questionnaire (30 questions) used to evaluate disease symptoms, functional impacts (eg, physical functioning), and HRQoL and to characterize clinical benefit from the patient perspective. The HRQoL score ranges from 0 to 100. A higher score indicates better QoL. A score change of 10 points was pre-defined as clinically meaningful. bd twice daily.
| Unit on scale | Olaparib 300 mg Twice Daily (bd) | Placebo |
|---|---|---|
| Adjusted Mean Change From Baseline up to 6 Months in Global Quality of Life (QoL) Score From the EORTC-QLQ-C30 Questionnaire | -1.03 (-3.826 to 1.759) | 1.18 (-2.585 to 4.939) |
To assess the safety and tolerability of olaparib maintenance monotherapy. SAE: serious adverse events CTCAE: Common Terminology Criteria for Adverse Events
| Participants | Olaparib 300 mg Twice Daily (bd) | Placebo |
|---|---|---|
| Any AE | 89 | 56 |
| Any AE of CTCAE Grade 3 or higher | 44 | 15 |
| Any AE with outcome = death | 1 | 0 |
| Any SAE (including events with outcome = death) | 28 | 10 |
| AnyAE leading to withdrawal of olaparib/placebo | 8 | 1 |
| Any AE leading to dose interruption | 38 | 4 |
| Any AE leading to dose reduction | 16 | 3 |
Collected over From informed consent until 30 days after last dose + subsequent treatment-related events reported (maximum up to 4 years).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Olaparib 300 mg Twice Daily (bd) | 68/92 (73.9%) | 28/90 (31.1%) | 89/90 (98.9%) |
| Placebo | 52/62 (83.9%) | 10/61 (16.4%) | 56/61 (91.8%) |
| Event | Olaparib 300 mg Twice Daily (bd) | Placebo |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 7/90 | 0/61 |
| VomitingGastrointestinal disorders | 1/90 | 3/61 |
| Abdominal painGastrointestinal disorders | 4/90 | 1/61 |
| PyrexiaGeneral disorders | 0/90 | 2/61 |
| CholangitisHepatobiliary disorders | 2/90 | 1/61 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 0/90 | 1/61 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/90 | 1/61 |
| Embolic strokeNervous system disorders | 0/90 | 1/61 |
| Cardiac failureCardiac disorders | 1/90 | 1/61 |
| Renal failureRenal and urinary disorders | 0/90 | 1/61 |
| Event | Olaparib 300 mg Twice Daily (bd) | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 44/90 | 15/61 |
| FatigueGeneral disorders | 42/90 | 16/61 |
| DiarrhoeaGastrointestinal disorders | 34/90 | 10/61 |
| Abdominal painGastrointestinal disorders | 26/90 | 15/61 |
| AnaemiaBlood and lymphatic system disorders | 26/90 | 10/61 |
| ConstipationGastrointestinal disorders | 25/90 | 7/61 |
| Back painMusculoskeletal and connective tissue disorders | 24/90 | 13/61 |
| Decreased appetiteMetabolism and nutrition disorders | 24/90 | 4/61 |
| VomitingGastrointestinal disorders | 23/90 | 9/61 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 19/90 | 11/61 |
Full analysis set consisted of all randomised patients analysed on an intent to treat basis.
| Age, Continuous(Years) | Olaparib 300 mg Twice Daily (bd) | Placebo | Total |
|---|---|---|---|
| Mean | 58.2 ± 10.27 | 56.4 ± 9.07 | 57.5 ± 9.81 |
| Sex: Female, Male(Participants) | Olaparib 300 mg Twice Daily (bd) | Placebo | Total |
|---|---|---|---|
| Female | 39 | 31 | 70 |
| Male | 53 | 31 | 84 |
| Ethnicity (NIH/OMB)(Participants) | Olaparib 300 mg Twice Daily (bd) | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 2 | 6 |
| Not Hispanic or Latino | 88 | 60 | 148 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Olaparib 300 mg Twice Daily (bd) | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 4 | 2 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 0 | 5 |
| White | 82 | 59 | 141 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
Showing the first 100 of 103 sites across 12 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Dec 2014 to primary completion in Jan 2019, 48 months.
Results were first posted in Jan 2020, 1 year after primary completion.
Of 84 phase 3 interventional studies under Pancreatic Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 77. This study's 48 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olaparib